# Partner Investment Management, L.P.

> Institutional holdings reported to the SEC as of Q4 2019 on Form 13F. CIK 1442276. Source: https://holderbook.com/funds/1442276-partner-investment-management-l-p/

- Reported value: $13.9M
- Positions: 41
- Weight of the ten largest: 48.1%
- Filed: 2020-02-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| AUDENTES THERAPEUTICS INC | [BOLD](https://holderbook.com/stocks/BOLD/) | $1.1M | 17,795 | 7.6% | 5 |
| ALEXION PHARMACEUTICALS INC | [ALXN](https://holderbook.com/stocks/ALXN/) | $911.0K | 8,421 | 6.5% | 2 |
| ALLENA PHARMACEUTICALS INC | [ALNAQ](https://holderbook.com/stocks/ALNAQ/) | $776.0K | 284,285 | 5.6% | 5 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $708.0K | 10,898 | 5.1% | 3 |
| PENUMBRA INC | [PEN](https://holderbook.com/stocks/PEN/) | $608.0K | 3,699 | 4.4% | 5 |
| ZIMMER BIOMET HOLDINGS INC | [ZBH](https://holderbook.com/stocks/ZBH/) | $552.0K | 3,689 | 4.0% | 5 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $546.0K | 1,839 | 3.9% | 1 |
| NEVRO CORP | [NVRO](https://holderbook.com/stocks/NVRO/) | $531.0K | 4,515 | 3.8% | 5 |
| ELEVANCE HEALTH INC FORMERLY | [ELV](https://holderbook.com/stocks/ELV/) | $504.0K | 1,669 | 3.6% | 1 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $494.0K | 1,347 | 3.5% | 1 |
| THE CIGNA GROUP | [CI](https://holderbook.com/stocks/CI/) | $453.0K | 2,216 | 3.3% | 2 |
| IQVIA HLDGS INC | [IQV](https://holderbook.com/stocks/IQV/) | $452.0K | 2,926 | 3.2% | 4 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $451.0K | 5,329 | 3.2% | 3 |
| AERIE PHARMACEUTICALS INC | [AERI](https://holderbook.com/stocks/AERI/) | $436.0K | 18,035 | 3.1% | 2 |
| ALLERGAN PLC | [AGN](https://holderbook.com/stocks/AGN/) | $436.0K | 2,282 | 3.1% | 4 |
| ARENA PHARMACEUTICALS INC | [ARNA](https://holderbook.com/stocks/ARNA/) | $431.0K | 9,484 | 3.1% | 5 |
| CENTENE CORP DEL | [CNC](https://holderbook.com/stocks/CNC/) | $430.0K | 6,838 | 3.1% | 1 |
| NOVARTIS AG | [NVS](https://holderbook.com/stocks/NVS/) | $392.0K | 4,270 | 2.8% | 2 |
| HCA HEALTHCARE INC | [HCA](https://holderbook.com/stocks/HCA/) | $345.0K | 2,335 | 2.5% | 5 |
| PFIZER INC | [PFE](https://holderbook.com/stocks/PFE/) | $294.0K | 7,492 | 2.1% | 1 |
| ICU MED INC | [ICUI](https://holderbook.com/stocks/ICUI/) | $258.0K | 1,381 | 1.9% | 1 |
| DERMIRA INC | [DERM](https://holderbook.com/stocks/DERM/) | $256.0K | 16,892 | 1.8% | 4 |
| ICON PUB LTD CO | [ICLR](https://holderbook.com/stocks/ICLR/) | $241.0K | 1,402 | 1.7% | 3 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $233.0K | 791 | 1.7% | 1 |
| IRHYTHM HOLDINGS INC | [IRTC](https://holderbook.com/stocks/IRTC/) | $231.0K | 3,389 | 1.7% | 5 |
| IMMUNOMEDICS INC | [IMMU](https://holderbook.com/stocks/IMMU/) | $230.0K | 10,880 | 1.7% | 1 |
| ABBOTT LABORATORIES | [ABT](https://holderbook.com/stocks/ABT/) | $223.0K | 2,565 | 1.6% | 1 |
| MOLINA HEALTHCARE INC | [MOH](https://holderbook.com/stocks/MOH/) | $188.0K | 1,387 | 1.3% | 5 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $184.0K | 788 | 1.3% | 5 |
| STANDARD BIOTOOLS INC | [LAB](https://holderbook.com/stocks/LAB/) | $132.0K | 37,856 | 0.9% | 4 |
| CATALENT INC | [CTLT](https://holderbook.com/stocks/CTLT/) | $126.0K | 2,231 | 0.9% | 3 |
| MorphoSys AG | - | $126.0K | 994 | 0.9% | 1 |
| ABBVIE INC | [ABBV](https://holderbook.com/stocks/ABBV/) | $112.0K | 1,269 | 0.8% | 1 |
| AXONICS INC | [AXNX](https://holderbook.com/stocks/AXNX/) | $110.0K | 3,978 | 0.8% | 2 |
| CARDIOVASCULAR SYS INC DEL | [CSII](https://holderbook.com/stocks/CSII/) | $96.0K | 1,985 | 0.7% | 5 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $95.0K | 434 | 0.7% | 1 |
| HALOZYME THERAPEUTICS INC | [HALO](https://holderbook.com/stocks/HALO/) | $82.0K | 4,650 | 0.6% | 1 |
| AMARIN CORP PLC | [AMRNXXXX](https://holderbook.com/stocks/AMRNXXXX/) | $81.0K | 3,757 | 0.6% | 1 |
| COHERUS ONCOLOGY INC | [CHRS](https://holderbook.com/stocks/CHRS/) | $68.0K | 3,771 | 0.5% | 4 |
| ACORDA THERAPEUTICS INC | [ACOR](https://holderbook.com/stocks/ACOR/) | $37.0K | 18,342 | 0.3% | 2 |
| ENDOLOGIX INC | [ELGXQ](https://holderbook.com/stocks/ELGXQ/) | $4.0K | 2,440 | 0.0% | 2 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2019 | +14.0% | +8.5% | +5.5% | 88% |
| Q3 2019 | -8.0% | +1.3% | -9.3% | 100% |
| Q2 2019 | +0.5% | +3.7% | -3.3% | 98% |
| Q1 2019 | +10.9% | +13.0% | -2.1% | 97% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2019 | $13.9M | 41 |
| Q3 2019 | $58.4M | 69 |
| Q2 2019 | $94.2M | 81 |
| Q1 2019 | $86.5M | 89 |
| Q4 2018 | $80.1M | 88 |